Despite this study providing a scoping review of the current literature on SGLT2 inhibitors and GLP-1 receptor agonists in Cardiovascular–Kidney–Metabolic syndrome, certain limitations should be addressed. This evidence concerns the gene SLC5A2 and metabolic syndrome.